Insulin independence for LCT
Tuesday, 07 April, 2009
New Zealand’s Living Cell Technologies has reported that a patient with type 1 diabetes is currently insulin independent following treatments in an early stage trial.
LCT is running the safety and dosing trial in Moscow. Seven patients have received Diabecell implants at a low or medium dose.
Diabecell is a microencapsulated product containing insulin-producing porcine islet cells. In the female patient, live porcine cells in their capsules have been found in the abdomen and porcine insulin was detected in her blood.
The 37-year-old had been on daily insulin injections for 15 years. She is now maintaining good blood glucose control without injections, LCT said.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
